PL377833A1 - Sposób rozdzielania amin przydatnych do leczenia zaburzeń związanych z zespołem oporności insulinowej - Google Patents

Sposób rozdzielania amin przydatnych do leczenia zaburzeń związanych z zespołem oporności insulinowej

Info

Publication number
PL377833A1
PL377833A1 PL377833A PL37783304A PL377833A1 PL 377833 A1 PL377833 A1 PL 377833A1 PL 377833 A PL377833 A PL 377833A PL 37783304 A PL37783304 A PL 37783304A PL 377833 A1 PL377833 A1 PL 377833A1
Authority
PL
Poland
Prior art keywords
treatment
useful
insulin resistance
disorders associated
resistance syndrome
Prior art date
Application number
PL377833A
Other languages
English (en)
Other versions
PL214955B1 (pl
Inventor
Gérard Moinet
Daniel Cravo
Thierry Passemar
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL377833A1 publication Critical patent/PL377833A1/pl
Publication of PL214955B1 publication Critical patent/PL214955B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Przedmiotem wynalazku jest sposób rozdzielania racemicznych związków aminowych pochodzących od dihydro-1,3,5-triazyn z odpowiedniej mieszaniny. Przedmiotem wynalazku są także enancjomery pochodnych aminowych dihydro-1,3,5-triazyn oraz ich zastosowanie do otrzymywania leków, w szczególności do leczenia cukrzycy i malrii.
PL377833A 2003-04-10 2004-04-06 Sposób rozdzielania amin przydatnych do leczenia zaburzen zwiazanych z zespolem opornosci insulinowej PL214955B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0304486A FR2853650B1 (fr) 2003-04-10 2003-04-10 Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Publications (2)

Publication Number Publication Date
PL377833A1 true PL377833A1 (pl) 2006-02-20
PL214955B1 PL214955B1 (pl) 2013-10-31

Family

ID=33041769

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377833A PL214955B1 (pl) 2003-04-10 2004-04-06 Sposób rozdzielania amin przydatnych do leczenia zaburzen zwiazanych z zespolem opornosci insulinowej

Country Status (23)

Country Link
US (1) US7501511B2 (pl)
EP (1) EP1611111B1 (pl)
JP (1) JP4836778B2 (pl)
KR (1) KR101107665B1 (pl)
CN (1) CN100383130C (pl)
AR (1) AR044511A1 (pl)
AT (1) ATE425151T1 (pl)
AU (1) AU2004228125B2 (pl)
BR (1) BRPI0409258B8 (pl)
CA (1) CA2521879C (pl)
CY (1) CY1109609T1 (pl)
DE (1) DE602004019897D1 (pl)
DK (1) DK1611111T3 (pl)
ES (1) ES2321718T3 (pl)
FR (1) FR2853650B1 (pl)
MX (1) MXPA05010764A (pl)
PL (1) PL214955B1 (pl)
PT (1) PT1611111E (pl)
RU (1) RU2344131C2 (pl)
SI (1) SI1611111T1 (pl)
TW (1) TWI344464B (pl)
WO (1) WO2004089917A2 (pl)
ZA (1) ZA200509071B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
CN101468986B (zh) * 2007-12-26 2010-12-29 香港南北兄弟国际投资有限公司 一种二氢嘧啶消旋化合物的拆分方法
DE102008007314A1 (de) * 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
CA2725011A1 (en) * 2008-05-23 2009-11-26 Poxel Sas Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
HRP20160318T1 (hr) 2008-07-29 2016-05-06 Poxel Postupak izolacije enantiomernih komponenti iz smjesa enantiomera pomoću kristalizacije kontrolirane veličinom čestica
DE102009014898A1 (de) * 2009-03-25 2010-09-30 Merck Patent Gmbh Prozess zur Enantiomerentrennung von 3,6-Dihydro-1,3,5-triazinderivaten
ES2436633T3 (es) * 2009-03-26 2014-01-03 Poxel Procedimiento para la separación de enantiómeros de dihidro-1,3,5-triazinas racémicas por cristalización preferencial
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
ES2577930T3 (es) * 2010-06-09 2016-07-19 Poxel Derivados de triazina para retrasar el inicio de la diabetes tipo 1
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
RS54397B1 (sr) * 2010-12-01 2016-04-28 Poxel Odvajanje enantiomera triazin derivata pomoću vinske kiseline
US11617754B2 (en) 2017-10-02 2023-04-04 Poxel Sa Methods of treating heart failure with preserved ejection fraction
MX2020013210A (es) 2018-06-06 2021-02-26 Metavant Sciences Gmbh Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica.
EP3806828A1 (en) 2018-06-14 2021-04-21 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
CN114763339A (zh) * 2021-01-13 2022-07-19 江苏恒瑞医药股份有限公司 三嗪衍生物的制备方法
CN115087643B (zh) * 2021-01-15 2023-10-27 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894027A (en) * 1973-07-31 1975-07-08 Merck & Co Inc Resolution of racemic reticuline and racemization of its enantiomers
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
JPH0436279A (ja) * 1990-06-01 1992-02-06 Kyowa Hakko Kogyo Co Ltd 光学活性なベンゾオキセピン誘導体の製造法
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
WO1997011074A1 (en) * 1995-09-22 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Novel processes for producing pyridoindole derivatives
MX9805870A (pl) * 1996-01-22 1999-01-31
JPH11193270A (ja) * 1997-12-26 1999-07-21 Koei Chem Co Ltd 光学活性１−メチル−３−ピペリジンメタノールの製造方法
JP4138928B2 (ja) * 1998-02-20 2008-08-27 山川薬品工業株式会社 Ｄ−アロイソロイシンの製造方法および製造の中間体
FR2775974B1 (fr) * 1998-03-16 2000-08-18 Rhodia Chimie Sa Procede de separation de diastereoisomeres d'une diphosphine et preparation de diphosphines optiquement actives
EP1091944A1 (en) * 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
JP2001199972A (ja) * 2000-01-20 2001-07-24 Eisai Co Ltd 光学活性ピペラジン誘導体の製造法
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
JP2002193933A (ja) * 2000-06-14 2002-07-10 Toray Ind Inc 光学活性ピペリジン誘導体またはその酸塩の製造方法
DE10042064A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10125131A1 (de) * 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram

Also Published As

Publication number Publication date
AR044511A1 (es) 2005-09-14
JP2006522753A (ja) 2006-10-05
WO2004089917A3 (en) 2004-12-23
DK1611111T3 (da) 2009-05-18
RU2344131C2 (ru) 2009-01-20
SI1611111T1 (sl) 2009-08-31
BRPI0409258B1 (pt) 2018-05-15
KR20050120791A (ko) 2005-12-23
ES2321718T3 (es) 2009-06-10
CN100383130C (zh) 2008-04-23
PL214955B1 (pl) 2013-10-31
US7501511B2 (en) 2009-03-10
CN1771233A (zh) 2006-05-10
PT1611111E (pt) 2009-06-18
DE602004019897D1 (de) 2009-04-23
ATE425151T1 (de) 2009-03-15
BRPI0409258A (pt) 2006-03-28
WO2004089917A2 (en) 2004-10-21
AU2004228125A1 (en) 2004-10-21
US20060223803A1 (en) 2006-10-05
TW200504037A (en) 2005-02-01
TWI344464B (en) 2011-07-01
BRPI0409258B8 (pt) 2021-05-25
CA2521879A1 (en) 2004-10-21
RU2005134685A (ru) 2006-06-10
CA2521879C (en) 2013-01-08
EP1611111A2 (en) 2006-01-04
FR2853650B1 (fr) 2006-07-07
MXPA05010764A (es) 2005-12-12
EP1611111B1 (en) 2009-03-11
ZA200509071B (en) 2007-04-25
KR101107665B1 (ko) 2012-01-20
JP4836778B2 (ja) 2011-12-14
CY1109609T1 (el) 2014-08-13
AU2004228125B2 (en) 2010-07-15
HK1088002A1 (en) 2006-10-27
FR2853650A1 (fr) 2004-10-15

Similar Documents

Publication Publication Date Title
TW200504037A (en) Process for resolving amines that are useful for the treatment of disorders associated with insulin resistance syndrome
RU2470011C2 (ru) Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
EA201200954A1 (ru) Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
WO2004085388A3 (en) Cyclic protein tyrosine kinase inhibitors
IS6922A (is) Heterófjölhringjaefnasambönd og notkun þeirra semmetabótrópísk mótlyf gegn glútamat viðtökum
SI1971601T1 (sl) N fenil kinazolin aminski derivati in sorodne spojine kot inhibitorji ERBB tip I receptorske tirozin kinaze za zdravljenje hiperproliferativnih bolezni
EA200601269A1 (ru) Лекарственное средство, содержащее производные фенилпиперазина
NO20060774L (no) Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
WO2006072608A3 (en) Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
DE602004018386D1 (de) Verfahren zur herstellung von 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on-hydrochlorid
PE20050079A1 (es) Derivados de pirrolidona como inhibidores de maob
NO20075086L (no) Behandling av Parkinsons sykdom, obstruktiv sovn apne, demens med Lewy legemer, vaskulaer demens med ikke-imidazol alkylamin histamin H3-reseptor ligander
CY1110775T1 (el) Υποκατεστημενα αμιδια του θειενοπυρρολιου του καρβοξυλικου οξεος, αμιδια της πυρρολοθειαζολης του καρβοξυλικου οξεος και σχετικα αναλογα ως αναστολεις της κινασης i εψιλον της καζεϊνης
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
ATE401304T1 (de) Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EA200500673A1 (ru) Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
ATE414516T1 (de) Morphinanderivate als mittel gegen juckreiz
WO2004052858A3 (en) Inhibitors of monoamine uptake
ATE552234T1 (de) Cyclohexanderivate und verfahren zu deren herstellung
MXPA05010678A (es) Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de recaptacion de serotonina.
MY140027A (en) Cyclic amine derivatives, process for their preparation and pharmaceuticals containing them
ATE469887T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz